Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes

Clin Gastroenterol Hepatol. 2008 Jul;6(7):828-31. doi: 10.1016/j.cgh.2008.03.005. Epub 2008 Jun 4.


Background & aims: Patients with diabetes are at risk for nonalcoholic fatty liver disease leading to advanced fibrosis, cirrhosis, and liver cancer. We examined the efficacy of a screening strategy with a noninvasive fibrosis biomarker (FibroTest) in patients with diabetes.

Methods: We prospectively studied 1131 consecutive patients without a history of liver disease seen for diabetes. The biomarker data were obtained, and patients with presumed advanced fibrosis were reinvestigated by a hepatologist using elastography and, if necessary, ultrasonography, endoscopy, or liver biopsy.

Results: The biomarker predicted advanced fibrosis in 63 of 1131 (5.6%) patients. A total of 45 patients was reinvestigated, and advanced fibrosis was confirmed in 32 patients, a 2.8% (32/1131) prevalence of confirmed advanced fibrosis, 5 cases of cirrhosis, and 4 cases of hepatocellular carcinoma. In the population with type 2 diabetes who were 45 years or older, the prevalence of confirmed advanced fibrosis was 4.3% (30/696), and hepatocellular carcinoma was 5.7 of 1000 (4/696).

Conclusions: The fibrosis biomarker might be used for the detection of advanced fibrosis in patients with type 2 diabetes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Biomarkers
  • Biopsy
  • Diabetes Complications*
  • Elasticity Imaging Techniques
  • Endoscopy
  • Female
  • Humans
  • Liver / pathology
  • Liver Cirrhosis / epidemiology*
  • Liver Function Tests / methods*
  • Male
  • Mass Screening / methods*
  • Middle Aged
  • Prevalence
  • Prospective Studies
  • Severity of Illness Index
  • Ultrasonography


  • Biomarkers